- Dermira to receive $30M upfront. Almira to get exclusive option to license rights for Dermira’s lebrikizumab to develop in dermatology & commercialize it in all indications in EU, with 45 days to exercise the option on basis of its P-IIb results
- If Almirall exercises its option, Dermira will receive $50M as option exercise fee, $30M milestones on the onset of P-III trial, $85M as regulatory milestone and on first sale in EU, and threshold milestones & royalties on net sales of lebrikizumab in EU
- Lebrikizumab is a mAb, bind to IL-13, involved in prevention of the formation of IL-13Rα1/IL-4Rα heterodimer complex and is evaluated in P-IIb study in 280 patients with moderate-to-severe atopic dermatitis aged >18yrs.
Click here to read full press release/ article | Ref: Globe Newswire | Image: Pharmaphorum